Skip to main content
OpenTrials
Completed

NCT Number: NCT04423237

Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients After HSCT

Hematopoietic Stem Cell Transplantation (HSCT) is currently a standard procedure for a wide range of blood-oncological diseases and genetic disorders. Recent improvements in transplant technologies, infection prevention and graft-versus-host-disease (GVHD) management procedures have significantly reduced the transplant-related mortality (TRM). However, approximately 50% of pediatric patients may develop liver dysfunction before HSCT and 74% to 85.5% after HSCT, with a TRM related to liver dysfunction reaching 46%. The liver and pancreas complications still remain too high for the difficulties and diagnostic inefficiencies and, consequently, for the lack of targeted and safer therapies. The diagnostic problems can be summarized in 3 major points: a) the histological examination of liver and pancreas parenchyma cannot be routinely performed because of the organ anatomy and the relative risk of the bioptic procedures; b) the lack of specific biomarkers or advanced imaging techniques appropriate for the diagnosis of HSCT complications; c) the multifactorial causes of organ complications, as well as drug toxicities, GVHD, siderosis, ductopenia (considered as an index of hepatic GVHD), the accumulation of potentially toxic substances favored by siderosis and ductopenia. In more than 50% of HSCT patients, siderosis and/or ductopenia may represent common pathological conditions. Furthermore, international guidelines issued by onco-hematology and transplantation scientific societies recommend a chelating treatment with deferasirox in all hematological and oncological patients undergoing an intense transfusion regimen. However, in the presence of siderosis and marked ductopenia, patients receiving deferasirox may experience both severe renal and hematological toxicities and lack of effectiveness of the chelating treatment.

Therefore, the principal aim of the present retrospective study will be the evaluation of the transplant-related mortality (TRM) in patients requiring a chelation treatment according to the Italian guidelines in pediatric patients

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Iron Overload Iron Metabolism Disorders Metabolic Diseases Nutritional and Metabolic Diseases

Age range

Up to 17 year

Sex eligibility

All sexes

Study type

Observational

Primary location

IRCCS Burlo Garofolo

Trieste, 34137, Italy

About this study

The present retrospective study will be conducted at the Bone Marrow Transplant Center, IRCCS Burlo Garofolo, Trieste, Italy. All pediatric patients who underwent one or more allogeneic HSCTs between 2010 and 2018 will be enrolled according to inclusion/exclusion criteria.

The following data will be collected in a retrospective manner:

  • Data on the underlying disease (diagnosis, therapeutic protocol, transfusion regimen, possible relapses, type of transplant, conditioning regimen, infectious complications, immunosuppressive treatment, including use of steroids);
  • Pre-transplant liver and pancreatic function, as well as quantification of iron content by nuclear magnetic resonance (MRI);
  • Pre-transplant histological evaluation of liver parenchyma in case of pre-existing liver disease;
  • Post-transplant liver and pancreatic function and the evaluation of parenchymal accumulation of Fe+;
  • Length and doses of DFX treatment, and corresponding drug plasma concentrations as per routine drug monitoring protocols;
  • Treatment tolerability according to CTC-AE grading V5.0, November 27, 2017 The post-transplant data will be collected within 2 years from HSCT (or the last HSCT when more than one).

The data entered in an appropriate anonymous database will be processed by descriptive statistics and uni- multivariate statistical analyses according to study endpoints. DFX plasma concentrations will be analyzed by means of to a nonlinear mixed effect modeling approach to elaborate a population pharmacokinetic (POP/PK) model. POP/PK findings will be further analyzed together with clinical and laboratory data.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • one or more allogeneic HSCT
  • any type of disease (blood-oncological or genetic), from any type of donor (sibling, MUD, haploidentical) and with any source of stem cells (spinal cord, peripheral blood stem cells, cord blood)
  • diagnosis of moderate-to-severe siderosis (by nuclear magnetic resonance imaging, MRI) and who needed a chelation treatment with deferasirox
  • one or more liver biopsies in the post-transplant period to perform histological examinations
  • Complete results from lab analyses
  • 2-year follow-up after HSCT
  • therapeutic drug monitoring (TDM) protocol for deferasirox plasma concentration as per clinical routine
  • Sign of the informed consent by the parents or legal representatives

Exclusion criteria

  • Lack of liver biopsies after transplantation, results from laboratory analyses or TDM or MRI
  • Lack of informed consent

Treatment and study plan

Deferasirox

Drug

DEFERASIROX administered as per clinical practice and according to technical note

Other names: Exjade or Deferasirox Milan

Primary outcomes

  1. Transplant-related mortality (TRM)

    Time frame: 0-24 months after transplant

    TRM in SIO/SIO+D patients treated with deferasirox as per Italian guidelines

Secondary outcomes

  1. Post-HSCT liver and pancreatic complications

    Time frame: 0-24 months after transplant

    Incidence of post-HSCT liver and pancreatic complications in SIO/SIO+D patients treated with deferasirox as per Italian guidelines

  2. Time to iron concentration normalization

    Time frame: 0-24 months after transplant

    The times required for the normalization of the Iron Concentration in SIO and SIO+D patients

  3. Statistical analysis of risk factors for ductopenia

    Time frame: 0-24 months after transplant

    The correlation between ductopenia and potential risk factors will be investigated by uni- and multi-variate analyses. The following data will be included in the analyses as potential risk factors: chemo-radiotherapy regimens prior to HSCT (drugs and doses), number of blood transfusions

  4. Minimum plasma concentrations of deferasirox

    Time frame: 0-24 months after transplant

    In SIO/SIO+D patients, a factorial analysis for mixed data and a nonlinear mixed effect modeling approach will be used to investigate plasma pharmacokinetics of deferasirox in terms of patients' exposure (minimum plasma concentration, Cmin) and to evaluate the effect of identified covariates on drug disposition.

  5. Correlation of minimum plasma concentrations of deferasirox with drug tolerability

    Time frame: 0-24 months after transplant

    In SIO/SIO+D patients, uni- and multi-variate analyses will be adopted to assess the correlation of Cmin with treatment tolerability

Sponsors and collaborators

Lead sponsor

University of Pisa

Other

Collaborators

  • IRCCS Burlo Garofolo
  • University of Genova

Registry information

Official study title

Identification of Risk Factors and Measures to Prevent Liver and Pancreas Complications in Pediatric Patients Undergoing a Hematopoietic Stem Cell Transplant (HSCT)

Important dates

Study start
2020
Primary completion
2024
Study completion
2024
First posted
Jun 9, 2020
Registry last updated
Jun 3, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.